Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 2, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the underwriters of its previously announced underwritten public offering of 5,500,000
Toggle Summary Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 27, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Analyst and Investor Event on the evening of March 4, 2018 , at the joint
Toggle Summary Aimmune Therapeutics Announces Closing of Public Offering of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 26, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the completion of its previously announced underwritten public offering of 5,500,000
Toggle Summary Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at
Toggle Summary Aimmune Therapeutics Announces Proposed Public Offering of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 20, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has commenced an underwritten public offering of up to $150,000,000 of shares of
Toggle Summary Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
Landmark 554-patient Phase 3 study met the primary efficacy endpoint, as 67.2% of AR101 patients ages 4–17 tolerated at least a 600-mg dose of peanut protein in the exit food challenge, compared to 4.0% of placebo patients (p
Toggle Summary Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
— New Members Join International Board of Leading Academic Experts in Allergy and Immunology — — Prof. du Toit Is Lead Author of Landmark LEAP and LEAP-On Studies on Prevention of Peanut Allergy in Young Children — — Dr. Shreffler Is a Renowned Expert on Immunologic Mechanisms of Food Allergy —
Toggle Summary Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 12, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data during a late-breaking oral abstract session and in poster
Toggle Summary Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy
— Newly Expanded Global Agreement Secures Exclusive Supply Relationship through 2033 — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 10, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced an
Toggle Summary Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— PALISADE Completed in 2017; Topline Results Anticipated in February — — Late-Breaking Abstract Presentation at the 2018 American Academy of Allergy , Asthma & Immunology–World Allergy Organization Joint Congress in March — — PALISADE Follow-On Study, ARC004, Fully Enrolled — — RAMSES Real-World